Skip to main content
SpringerLink
Log in

Pediatric Hodgkin Lymphoma

  • Chapter
  • First Online:
Hodgkin Lymphoma

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 1066 Accesses

Abstract

As we start the third decade of the third millennium AD, children with Hodgkin lymphoma (HL) continue to be treated differently from adults. The primary driving force for this divergence over the last 15–20 years has been a desire to reduce the burden of treatment with particular reference to late effects. That reduction is being achieved primarily by limiting the amount of radiotherapy required to maintain excellent EFS rates. Titration of therapeutic aggressiveness by the use of PET/CT response assessment scans has been instrumental in achieving this goal. Children and adolescents with early-stage lymphocyte predominant (NLP) HL are treated on, or according to, dedicated clinical trials employing surgery alone in select situations, and low dose NHL-like therapy, often without radiotherapy. The use of combination anti-CD 20 antibody therapy is also increasing in this pediatric population. Management of teenagers and young adults (TYA) straddles between the pediatric and adult approaches depending on the treating institution. Awareness of the specific needs of this age group is escalating and several “pediatric” trials have been extended to include young adults. International harmonization of prognostic factors, risk categorization, and response assessment remains a challenge. The treatment of pediatric and adolescent refractory disease and relapse, however, converges with the adult approach. Trials using anti-CD30 antibody alone or in combination with PD-1 inhibitors and other checkpoint inhibitors are ongoing currently as a bridge to transplant. The debate regarding which sort of stem cell “transplant,” when, and after what continues. It is gratifying that advances in treating pediatric HL continue, and we are confident that the future will bring more.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Notes

  1. 1.

    Mini-BEAM; BCNU, etoposide, cytarabine, melphalan

  2. 2.

    ESHAP, etoposide, methylprednisolone, cytarabine, cisplatin; DHAP, dexamethasone, cytarabine, cisplatin; APPE, cytarabine, cisplatin, prednisone, etoposide; DECAL, cytarabine, cisplatin, prednisone, etoposide, asparaginase

  3. 3.

    EPIC, etoposide, vincristine epirubicin, prednisolone; IEP, ifosfamide, etoposide, prednisolone; ICE, ifosfamide, carboplatin, etoposide; IV, ifosfamide, vinorelbine

  4. 4.

    GV gemcitabine, vinorelbine; IGEV, ifosfamide, gemcitabine, vinorelbine, prednisolone

References

  1. Rubin P, Williams JP, Devesa SS, Travis LB, Constine LS (2010) Cancer genesis across the age spectrum: associations with tissue development, maintenance, and senescence. Semin Radiat Oncol 20:3–11

    Article  PubMed  Google Scholar 

  2. Punnett A, Tsang RW, Hodgson DC (2010) Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol 20:30–44

    Article  PubMed  Google Scholar 

  3. Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS (2009) Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol 144:24–40

    Article  PubMed  Google Scholar 

  4. Foltz LM, Song KW, Connors JM (2006) Hodgkin’s lymphoma in adolescents. J Clin Oncol 24:2520–2526

    Article  PubMed  Google Scholar 

  5. Donaldson SS, Kaplan HS (1982) Complications of treatment of Hodgkin’s disease in children. Cancer Treat Rep 66:977–989

    CAS  PubMed  Google Scholar 

  6. Mauch PM, Weinstein H, Botnick L, Belli J, Cassady JR (1983) An evaluation of long-term survival and treatment complications in children with Hodgkin’s disease. Cancer 51:925–932

    Article  CAS  PubMed  Google Scholar 

  7. Merchant TE, Nguyen L, Nguyen D, Wu S, Hudson MM, Kaste SC (2004) Differential attenuation of clavicle growth after asymmetric mantle radiotherapy. Int J Radiat Oncol Biol Phys 59:556–561

    Article  PubMed  Google Scholar 

  8. Probert JC, Parker BR, Kaplan HS (1973) Growth retardation in children after megavoltage irradiation of the spine. Cancer 32:634–639

    Article  CAS  PubMed  Google Scholar 

  9. Donaldson SS, Glatstein E, Rosenberg SA, Kaplan HS (1976) Pediatric Hodgkin’s disease. II. Results of therapy. Cancer 37:2436–2447

    Article  CAS  PubMed  Google Scholar 

  10. Hodgson DC, Hudson MM, Constine LS (2007) Pediatric Hodgkin lymphoma: maximizing efficacy and minimizing toxicity. Semin Radiat Oncol 17:230–242

    Article  PubMed  Google Scholar 

  11. Constine LS, Donaldson SS, McDougall IR, Cox RS, Link MP, Kaplan HS (1984) Thyroid dysfunction after radiotherapy in children with Hodgkin’s disease. Cancer 53:878–883

    Article  CAS  PubMed  Google Scholar 

  12. Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N et al (2000) Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the childhood cancer survivor study. J Clin Endocrinol Metab 85:3227–3232

    CAS  PubMed  Google Scholar 

  13. Adams MJ, Hardenbergh PH, Constine LS, Lipshultz SE (2003) Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 45:55–75

    Article  PubMed  Google Scholar 

  14. Hancock SL, Donaldson SS, Hoppe RT (1993) Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol 11:1208–1215

    Article  CAS  PubMed  Google Scholar 

  15. Kung FH, Schwartz CL, Ferree CR, London WB, Ternberg JL, Behm FG et al (2006) POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA1 Hodgkin disease: a report from the Children’s oncology group. J Pediatr Hematol Oncol 28:362–368

    Article  CAS  PubMed  Google Scholar 

  16. Weiner MA, Leventhal B, Brecher ML, Marcus RB, Cantor A, Gieser PW et al (1997) Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin’s disease in pediatric patients: a pediatric oncology group study. J Clin Oncol 15:2769–2779

    Article  CAS  PubMed  Google Scholar 

  17. Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R et al (2009) A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 114:2051–2059

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348:2386–2395

    Article  CAS  PubMed  Google Scholar 

  19. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA, Stanford V (2002) Radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 20:630–637

    PubMed  Google Scholar 

  20. Mauz-Körholz C, Metzger ML, Kelly KM, Schwartz CL, Castellanos ME, Dieckmann K, Kluge R, Körholz D (2015) Pediatric Hodgkin lymphoma. J Clin Oncol 33(27):2975–2985

    Article  CAS  PubMed  Google Scholar 

  21. Keller FG, Castellino SM, Chen L, Pei Q, Voss SD, McCarten KM et al (2018) Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: a report from the Children’s Oncology Group. Cancer 124:3210–3219

    Article  CAS  PubMed  Google Scholar 

  22. Friedman DL, Chen L, Wolden S, Buxton A, McCarten K, FitzGerald TJ et al (2014) Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children’s Oncology Group Study AHOD0031. J Clin Oncol 32:3651–3658

    Article  PubMed  PubMed Central  Google Scholar 

  23. Mauz-Korholz C. Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents. ClinicalTrials.gov Identifier: NCT02684708. https://clinicaltrials.gov/ct2/show/NCT02684708

  24. Kaldor JM, Day NE, Clarke EA, Van Leeuwen FE, Henry-Amar M, Fiorentino MV et al (1990) Leukemia following Hodgkin’s disease. N Engl J Med 322:7–13

    Article  CAS  PubMed  Google Scholar 

  25. Mackie EJ, Radford M, Shalet SM (1996) Gonadal function following chemotherapy for childhood Hodgkin’s disease. Med Pediatr Oncol 27:74–78

    Article  CAS  PubMed  Google Scholar 

  26. Ortin TT, Shostak CA, Donaldson SS (1990) Gonadal status and reproductive function following treatment for Hodgkin’s disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys 19:873–880

    Article  CAS  PubMed  Google Scholar 

  27. van den Berg H, Furstner F, van den Bos C, Behrendt H (2004) Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease. Pediatr Blood Cancer 42:210–215

    Article  PubMed  Google Scholar 

  28. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES et al (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478–1484

    CAS  PubMed  Google Scholar 

  29. Hunger SP, Link MP, Donaldson SS (1994) ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin’s disease: the Stanford experience. J Clin Oncol 12:2160–2166

    Article  CAS  PubMed  Google Scholar 

  30. Bramswig JH, Heimes U, Heiermann E, Schlegel W, Nieschlag E, Schellong G (1990) The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin’s disease during childhood or adolescence. Cancer 65:1298–1302

    Article  CAS  PubMed  Google Scholar 

  31. Schellong G, Hornig I, Bramswig J, Bokkerink JP, Steinhoff A, Ludwig R et al (1988) Significance of procarbazine in the chemotherapy of Hodgkin’s disease--a report of the cooperative therapy study DAL-HD-85. Klin Padiatr 200:205–213

    Article  CAS  PubMed  Google Scholar 

  32. Bonadonna G (1982) Santoro a. ABVD chemotherapy in the treatment of Hodgkin’s disease. Cancer Treat Rev 9:21–35

    Article  CAS  PubMed  Google Scholar 

  33. Dorffel W, Luders H, Ruhl U, Albrecht M, Marciniak H, Parwaresch R et al (2003) Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin’s disease in children and adolescents: analysis and outlook. Klin Padiatr 215:139–145

    Article  CAS  PubMed  Google Scholar 

  34. Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J et al (2002) Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol 20:3765–3771

    Article  PubMed  Google Scholar 

  35. Wolden SL, Chen L, Kelly KM, Herzog P, Gilchrist GS, Thomson J et al (2012) Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin’s lymphoma--a report from the Children’s oncology group. J Clin Oncol 30:3174–3180

    Article  PubMed  PubMed Central  Google Scholar 

  36. Landman-Parker J, Pacquement H, Leblanc T, Habrand JL, Terrier-Lacombe MJ, Bertrand Y et al (2000) Localized childhood Hodgkin’s disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 18:1500–1507

    Article  CAS  PubMed  Google Scholar 

  37. Ruhl U, Albrecht M, Dieckmann K, Luders H, Marciniak H, Schellenberg D et al (2001) Response-adapted radiotherapy in the treatment of pediatric Hodgkin’s disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 51:1209–1218

    Article  CAS  PubMed  Google Scholar 

  38. Dorffel W, Ruhl U, Luders H, Claviez A, Albrecht M, Bokkerink J et al (2013) Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol 31:1562–1568

    Article  CAS  PubMed  Google Scholar 

  39. Schellong G (1996) Treatment of children and adolescents with Hodgkin’s disease: the experience of the German-Austrian Paediatric study group. Baillieres Clin Haematol 9:619–634

    Article  CAS  PubMed  Google Scholar 

  40. Mauz-Korholz C, Hasenclever D, Dorffel W, Ruschke K, Pelz T, Voigt A et al (2010) Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: the GPOH-HD-2002 study. J Clin Oncol 28:3680–3686

    Article  CAS  PubMed  Google Scholar 

  41. Keller FG, Nachman J, Constine L et al (2010) A phase III study for the treatment of children and adolescents with newly diagnosed low risk Hodgkin lymphoma (HL). ASH Annual Meeting. Blood 116(21):767

    Article  Google Scholar 

  42. Donaldson SS, Hudson MM, Lamborn KR, Link MP, Kun L, Billett AL et al (2002) VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin’s disease: results of a prospective clinical trial. J Clin Oncol 20:3081–3087

    Article  CAS  PubMed  Google Scholar 

  43. Tebbi CKMN, Schwartz C, Williams J (2001) Response dependent treatment of stages IA, IIA, and IIIA1 micro Hodgkin’s disease with ABVE and low dose involved field irradiation with or without dexrazoxane. Leuk Lymphoma 42:100

    Google Scholar 

  44. Shahidi M, Kamangari N, Ashley S, Cunningham D, Horwich A (2006) Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother Oncol 78:1–5

    Article  PubMed  Google Scholar 

  45. Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y et al (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79:270–277

    Article  PubMed  Google Scholar 

  46. Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT et al (2014) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 89:854–862

    Article  PubMed  Google Scholar 

  47. Terezakis SA, Metzger ML, Hodgson DC, Schwartz CL, Advani R, Flowers CR et al (2014) ACR appropriateness criteria pediatric Hodgkin lymphoma. Pediatr Blood Cancer 61:1305–1312

    Article  PubMed  Google Scholar 

  48. Hodgson DC, Dieckmann K, Terezakis S, Constine L, International Lymphoma Radiation Oncology G (2015) Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. Pract Radiat Oncol 5:85–92

    Article  PubMed  Google Scholar 

  49. Hoppe BS, Flampouri S, Su Z, Latif N, Dang NH, Lynch J et al (2012) Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 84:449–455

    Article  PubMed  Google Scholar 

  50. Korholz D, Claviez A, Hasenclever D, Kluge R, Hirsch W, Kamprad F et al (2004) The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin’s disease: evolution in the tradition of the DAL/GPOH studies. Klin Padiatr 216:150–156

    Article  CAS  PubMed  Google Scholar 

  51. Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A et al (2012) Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA 307:2609–2616

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Kelly KM, Hodgson D, Appel B, Chen L, Cole PD, Horton T et al (2013) Children’s oncology Group’s 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer 60:972–978

    Article  PubMed  Google Scholar 

  53. Korholz D, Kluge R, Wickmann L, Hirsch W, Luders H, Lotz I et al (2003) Importance of F18-fluorodeoxy-D-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin’s lymphoma in childhood and adolescence – consequences for the GPOH-HD 2003 protocol. Onkologie 26:489–493

    CAS  PubMed  Google Scholar 

  54. Weiner MA, Leventhal BG, Marcus R, Brecher M, Ternberg J, Behm FG et al (1991) Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin’s disease in pediatric patients: a pediatric oncology group study. J Clin Oncol 9:1591–1598

    Article  CAS  PubMed  Google Scholar 

  55. Oberlin O, Leverger G, Pacquement H, Raquin MA, Chompret A, Habrand JL et al (1992) Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin’s disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol 10:1602–1608

    Article  CAS  PubMed  Google Scholar 

  56. Vecchi V, Pileri S, Burnelli R, Bontempi N, Comelli A, Testi AM et al (1993) Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients. Cancer 72:2049–2057

    Article  CAS  PubMed  Google Scholar 

  57. Shankar AG, Ashley S, Radford M, Barrett A, Wright D, Pinkerton CR (1997) Does histology influence outcome in childhood Hodgkin’s disease? Results from the United Kingdom Children’s Cancer Study Group. J Clin Oncol 15:2622–2630

    Article  CAS  PubMed  Google Scholar 

  58. Hudson MM, Krasin M, Link MP, Donaldson SS, Billups C, Merchant TE et al (2004) Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin’s disease. J Clin Oncol 22:4541–4550

    Article  CAS  PubMed  Google Scholar 

  59. Atra A, Higgs E, Capra M, Elsworth A, Imeson J, Radford M et al (2002) ChlVPP chemotherapy in children with stage IV Hodgkin’s disease: results of the UKCCSG HD 8201 and HD 9201 studies. Br J Haematol 119:647–651

    Article  CAS  PubMed  Google Scholar 

  60. Friedman DL, Wolden S, Constine LS, et al AHOD0031: a phase III study of dose-intensive therapy for intermediate risk Hodgkin lymphoma: a report from the Children’s Oncology Group 2010. p. 766

    Google Scholar 

  61. Friedmann AM, Hudson MM, Weinstein HJ, Donaldson SS, Kun L, Tarbell NJ et al (2002) Treatment of unfavorable childhood Hodgkin’s disease with VEPA and low-dose, involved-field radiation. J Clin Oncol 20:3088–3094

    Article  CAS  PubMed  Google Scholar 

  62. Carde P, MacKintosh FR, Rosenberg SA (1983) A dose and time response analysis of the treatment of Hodgkin’s disease with MOPP chemotherapy. J Clin Oncol 1:146–153

    Article  CAS  PubMed  Google Scholar 

  63. De Vita VT Jr, Hubbard SM, Longo DL (1990) Treatment of Hodgkin’s disease. J Natl Cancer Inst Monogr 10:19–28

    Google Scholar 

  64. van Rijswijk RE, Haanen C, Dekker AW, de Meijer AJ, Verbeek J (1989) Dose intensity of MOPP chemotherapy and survival in Hodgkin’s disease. J Clin Oncol 7:1776–1782

    Article  PubMed  Google Scholar 

  65. Kelly KM, Cole PD, Chen L, Roberts KB, Hodgson DC, McCarten K, et al. Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children’s Oncology Group. 57th ASH Annual Meeting 2015. p. 3927

    Google Scholar 

  66. Kelly KM, Hutchinson RJ, Sposto R, Weiner MA, Lones MA, Perkins SL et al (2002) Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin’s lymphoma: preliminary results from the Children's cancer group study CCG-59704. Ann Oncol 13(Suppl 1):107–111

    Article  PubMed  Google Scholar 

  67. Charpentier AM, Friedman DL, Wolden S, Schwartz C, Gill B, Sykes J et al (2016) Predictive factor analysis of response-adapted radiation therapy for chemotherapy-sensitive pediatric Hodgkin lymphoma: analysis of the Children’s oncology group AHOD 0031 trial. Int J Radiat Oncol Biol Phys 96:943–950

    Article  PubMed  PubMed Central  Google Scholar 

  68. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A et al (2018) Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 378:331–344

    Article  CAS  PubMed  Google Scholar 

  69. Mason DY, Banks PM, Chan J, Cleary ML, Delsol G, de Wolf Peeters C et al (1994) Nodular lymphocyte predominance Hodgkin’s disease. A distinct clinicopathological entity. Am J Surg Pathol 18:526–530

    Article  CAS  PubMed  Google Scholar 

  70. Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E et al (1999) Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European task force on lymphoma project on lymphocyte-predominant Hodgkin’s disease. J Clin Oncol 17:776–783

    Article  CAS  PubMed  Google Scholar 

  71. Shankar A, Hall GW, Gorde-Grosjean S, Hasenclever D, Leblanc T, Hayward J et al (2012) Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin’s lymphoma – an Anglo-French collaborative report. Eur J Cancer 48:1700–1706

    Article  PubMed  Google Scholar 

  72. Sandoval C, Venkateswaran L, Billups C, Slim M, Jayabose S, Hudson MM (2002) Lymphocyte-predominant Hodgkin disease in children. J Pediatr Hematol Oncol 24:269–273

    Article  PubMed  Google Scholar 

  73. Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D, Shankar A, Dorffel W, Wallace WH et al (2007) Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 110:179–185

    Article  PubMed  Google Scholar 

  74. Appel B, Ehrlich P, Chen L, et al. Treatment of pediatric stage IA lymphocyte-predominant Hodgkin lymphoma with surgical resection alone: a report from the Children’s Oncology Group. ASCO Annual Meeting 2012. p. 9524

    Google Scholar 

  75. Murphy SB, Morgan ER, Katzenstein HM, Kletzel M (2003) Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol 25:684–687

    Article  PubMed  Google Scholar 

  76. Pellegrino B, Terrier-Lacombe MJ, Oberlin O, Leblanc T, Perel Y, Bertrand Y et al (2003) Lymphocyte-predominant Hodgkin’s lymphoma in children: therapeutic abstention after initial lymph node resection--a study of the French Society of Pediatric Oncology. J Clin Oncol 21:2948–2952

    Article  CAS  PubMed  Google Scholar 

  77. Hall GW, Katzilakis N, Pinkerton CR, Nicolin G, Ashley S, McCarthy K et al (2007) Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma – a Children’s cancer and Leukaemia group report. Br J Haematol 138:761–768

    Article  CAS  PubMed  Google Scholar 

  78. Appel B, Chen L, Hutchinson RJ, Hodgson D, Ehrlich P, Constine L et al (2014) Treatment of pediatric lymphocyte predominant Hodgkin lymphoma (LPHL): a report from the Children’s Oncology Group. Klin Padiatr 226:10

    Article  Google Scholar 

  79. Biasoli I, Stamatoullas A, Meignin V, Delmer A, Reman O, Morschhauser F et al (2010) Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the adult lymphoma study group. Cancer 116:631–639

    Article  PubMed  Google Scholar 

  80. Wickert RS, Weisenburger DD, Tierens A, Greiner TC, Chan WC (1995) Clonal relationship between lymphocytic predominance Hodgkin’s disease and concurrent or subsequent large-cell lymphoma of B lineage. Blood 86:2312–2320

    Article  CAS  PubMed  Google Scholar 

  81. Advani RH, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y et al (2014) Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol 32:912–918

    Article  CAS  PubMed  Google Scholar 

  82. Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P et al (2012) Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 119:1665–1670

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M et al (2005) Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the bone marrow transplant survivor study. Blood 105:4215–4222

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Baker KS, Gordon BG, Gross TG, Abromowitch MA, Lyden ER, Lynch JC et al (1999) Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin’s disease in children and adolescents. J Clin Oncol 17:825–831

    Article  CAS  PubMed  Google Scholar 

  85. Claviez A, Sureda A, Schmitz N (2008) Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin’s lymphoma. Bone Marrow Transplant 42(Suppl 2):S16–S24

    Article  PubMed  Google Scholar 

  86. Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP et al (2004) High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin’s disease: results and prognostic indices. J Clin Oncol 22:4532–4540

    Article  PubMed  Google Scholar 

  87. Schellong G, Dorffel W, Claviez A, Korholz D, Mann G, Scheel-Walter HG et al (2005) Salvage therapy of progressive and recurrent Hodgkin’s disease: results from a multicenter study of the pediatric DAL/GPOH-HD Study Group. J Clin Oncol 23:6181–6189

    Article  PubMed  Google Scholar 

  88. Gorde-Grosjean S, Oberlin O, Leblanc T, Pacquement H, Donadieu J, Lambilliotte A et al (2012) Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Societe Francaise de Lutte contre le cancer des Enfants et des adolescents (SFCE). Br J Haematol 158:649–656

    Article  PubMed  Google Scholar 

  89. Akhtar S, El Weshi A, Rahal M, Abdelsalam M, Al Husseini H, Maghfoor I (2010) High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin’s lymphoma. Bone Marrow Transplant 45:476–482

    Article  CAS  PubMed  Google Scholar 

  90. Williams CD, Goldstone AH, Pearce R, Green S, Armitage JO, Carella A et al (1993) Autologous bone marrow transplantation for pediatric Hodgkin’s disease: a case-matched comparison with adult patients by the European bone marrow transplant group lymphoma registry. J Clin Oncol 11:2243–2249

    Article  CAS  PubMed  Google Scholar 

  91. Moskowitz AJ, Schoder H, Gavane S, Thoren KL, Fleisher M, Yahalom J et al (2017) Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood 130:2196–2203

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Constine LS, Yahalom J, Ng AK, Hodgson DC, Wirth A, Milgrom SA et al (2018) The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 100:1100–1118

    Article  PubMed  Google Scholar 

  93. Chen AR, Hutchison R, Hess A et al (2007) Clinical outcomes of patients with recurrent/refractory Hodgkin disease receiving cyclosporine, interferon-V and interleukin-2 immunotherapy to induce autoreactivity after autologous stem cell transplantation with BEAM: a COG study. Blood 110:1896

    Google Scholar 

  94. Frankovich J, Donaldson SS, Lee Y, Wong RM, Amylon M, Verneris MR (2001) High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin’s disease: atopy predicts idiopathic diffuse lung injury syndromes. Biol Blood Marrow Transplant 7:49–57

    Article  CAS  PubMed  Google Scholar 

  95. Stoneham S, Ashley S, Pinkerton CR, Wallace WH, Shankar AG, United Kingdom Children’s Cancer Study G (2004) Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol 26:740–745

    Article  PubMed  Google Scholar 

  96. Bradley MB, Cairo MS (2008) Stem cell transplantation for pediatric lymphoma: past, present and future. Bone Marrow Transplant 41:149–158

    Article  CAS  PubMed  Google Scholar 

  97. Claviez A, Canals C, Dierickx D, Stein J, Badell I, Pession A et al (2009) Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 114:2060–2067

    Article  CAS  PubMed  Google Scholar 

  98. Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S et al (2018) Brentuximab vedotin for paediatric relapsed or refractory Hodgkin’s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol 5:e450–ee61

    Article  PubMed  Google Scholar 

  99. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30:2183–2189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Harker-Murray P, Leblanc T, Mascarin M, Mauz-Körholz C, Michel G, Cooper S et al (2018) Response-adapted therapy with Nivolumab and Brentuximab Vedotin (BV), followed by BV and Bendamustine for suboptimal response, in children, adolescents, and young adults with standard-risk relapsed/refractory classical Hodgkin lymphoma. 60th ASH Annual Meeting. Blood:927

    Google Scholar 

  101. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372:311–319

    Article  CAS  PubMed  Google Scholar 

  102. Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J et al (2016) Programmed Death-1 blockade with Pembrolizumab in patients with classical Hodgkin lymphoma after Brentuximab Vedotin failure. J Clin Oncol 34:3733–3739

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J et al (2018) Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 132:40–48

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Marina NM, Greenwald CA, Fairclough DL, Thompson EI, Wilimas JA, Mackert PW et al (1995) Serial pulmonary function studies in children treated for newly diagnosed Hodgkin’s disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Cancer 75:1706–1711

    Article  CAS  PubMed  Google Scholar 

  105. Mefferd JM, Donaldson SS, Link MP (1989) Pediatric Hodgkin’s disease: pulmonary, cardiac, and thyroid function following combined modality therapy. Int J Radiat Oncol Biol Phys 16:679–685

    Article  CAS  PubMed  Google Scholar 

  106. Green DM, Hall B (1988) Pregnancy outcome following treatment during childhood or adolescence for Hodgkin’s disease. Pediatr Hematol Oncol 5:269–277

    Article  CAS  PubMed  Google Scholar 

  107. Hudson MM, Poquette CA, Lee J, Greenwald CA, Shah A, Luo X et al (1998) Increased mortality after successful treatment for Hodgkin’s disease. J Clin Oncol 16:3592–3600

    Article  CAS  PubMed  Google Scholar 

  108. Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L et al (2004) Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 22:3139–3148

    Article  PubMed  Google Scholar 

  109. Green DM, Hyland A, Chung CS, Zevon MA, Hall BC (1999) Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. J Clin Oncol 17:3207–3215

    Article  CAS  PubMed  Google Scholar 

  110. Wolden SL, Lamborn KR, Cleary SF, Tate DJ, Donaldson SS (1998) Second cancers following pediatric Hodgkin’s disease. J Clin Oncol 16:536–544

    Article  CAS  PubMed  Google Scholar 

  111. Sankila R, Garwicz S, Olsen JH, Dollner H, Hertz H, Kreuger A et al (1996) Risk of subsequent malignant neoplasms among 1,641 Hodgkin’s disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol 14:1442–1446

    Article  CAS  PubMed  Google Scholar 

  112. Holmqvist AS, Chen Y, Berano Teh J, Sun C, Birch JM, van den Bos C et al (2019) Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma-identification of high-risk populations to guide surveillance: a report from the late effects study group. Cancer 125(8):1373–1383

    Article  CAS  PubMed  Google Scholar 

  113. Green DM, Hyland A, Barcos MP, Reynolds JA, Lee RJ, Hall BC et al (2000) Second malignant neoplasms after treatment for Hodgkin’s disease in childhood or adolescence. J Clin Oncol 18:1492–1499

    Article  CAS  PubMed  Google Scholar 

  114. Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F et al (1996) Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 334:745–751

    Article  CAS  PubMed  Google Scholar 

  115. Metayer C, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E et al (2000) Second cancers among long-term survivors of Hodgkin’s disease diagnosed in childhood and adolescence. J Clin Oncol 18:2435–2443

    Article  CAS  PubMed  Google Scholar 

  116. Constine LS, Tarbell N, Hudson MM, Schwartz C, Fisher SG, Muhs AG et al (2008) Subsequent malignancies in children treated for Hodgkin’s disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys 72:24–33

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

Thanks to Laura Finger, Rochester, for her help with the final draft and references of the third edition 2019.

Author information

Authors and Affiliations

  1. Pediatric and Adolescent Haematology/Oncology Unit, Children’s Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, UK

    Georgina W. Hall

  2. Division of Pediatric Hematology Oncology and BMT, Medical College of WI, Milwaukee, WI, USA

    Cindy Schwartz

  3. Children and Young People’s Cancer Services, Division of Paediatrics, University College Hospital, London, UK

    Stephen Daw

  4. Department of Radiation Oncology and Pediatrics, University of Rochester Medical Center, Rochester, NY, USA

    Louis S. Constine

Authors
  1. Georgina W. Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cindy Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen Daw
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Louis S. Constine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georgina W. Hall .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University Hospital Cologne, Köln, Nordrhein-Westfalen, Germany

    Andreas Engert

  2. Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Anas Younes

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hall, G.W., Schwartz, C., Daw, S., Constine, L.S. (2020). Pediatric Hodgkin Lymphoma. In: Engert, A., Younes, A. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-32482-7_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-32482-7_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-32481-0

  • Online ISBN: 978-3-030-32482-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation